Tag: Daiichi Sankyo

September 10, 2019 Off

Daiichi Sankyo’s U3-1402 show reduction in tumor size in testing

By Dino Mustafić

Daiichi Sankyo’s test of HER3 antibody drug conjugate U3-1402 data suggest that targeting HER3 with may be an effective treatment strategy irrespective of mechanism of resistance identified in the setting of EGFR TKI resistance, where new precision treatments are needed, said Helena Yu, MD, Medical Oncologist, Memorial Sloan Kettering Cancer Center, and a trial investigator.